This suggests that blocking CLPTM1L can markedly affect radioresistant NSCLC cells, whereas it has a weak effect on other cancer cells or normal cells because of the low levels of CLPTM1L in these cells. The gene discussed is CLPTM1L; the disease is non-small cell lung carcinoma.